Principal Financial Group Inc Vaxart, Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.71 - $1.25 $1,031 - $1,816	1,453 Added 3.87%	39,019 $29,000
Q4 2022 Feb 09, 2023	BUY	$0.75 - $2.24 $6,789 - $20,278	9,053 Added 31.75%	37,566 $36,000
Q3 2022 Nov 09, 2022	BUY	$2.09 - $4.5 $11,386 - $24,516	5,448 Added 23.62%	28,513 $62,000
Q2 2022 Aug 10, 2022	SELL	$2.7 - $5.28 $32,616 - $63,782	-12,080 Reduced 34.37%	23,065 $80,000
Q1 2022 May 09, 2022	BUY	$4.29 - $6.64 $2,848 - $4,408	664 Added 1.93%	35,145 $177,000
Q4 2021 Feb 09, 2022	SELL	$5.77 - $7.96 $72,702 - $100,296	-12,600 Reduced 26.76%	34,481 $216,000
Q3 2021 Nov 09, 2021	BUY	$6.67 - $9.8 $8,550 - $12,563	1,282 Added 2.8%	47,081 $374,000
Q2 2021 Aug 10, 2021	SELL	$5.06 - $10.78 $3.8 Million - $8.1 Million	-751,265 Reduced 94.25%	45,799 $343,000
Q1 2021 May 10, 2021	BUY	$5.64 - $23.33 $425,656 - $1.76 Million	75,471 Added 10.46%	797,064 $4.82 Million
Q4 2020 Feb 08, 2021	BUY	$3.5 - $7.98 $2.53 Million - $5.76 Million	721,593 New	721,593 $4.12 Million

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.